<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39423949</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-3511</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>16</Day></PubDate></JournalIssue><Title>International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases</Title><ISOAbbreviation>Int J Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Prevalence, risk factors and the impact of tenofovir treatment in SARS-CoV-2 infection and COVID-19 disease among people living with HIV. A cross-sectional population-based study.</ArticleTitle><Pagination><StartPage>107266</StartPage><MedlinePgn>107266</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijid.2024.107266</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1201-9712(24)00337-0</ELocationID><Abstract><AbstractText>The prevalence and risk factors of SARS-CoV-2 infection among unvaccinated people living with HIV (PWH) are not well understood, and the protective role of tenofovir remains controversial. This study aimed to assess the SARS-CoV-2 prevalence and associated risk factors among unvaccinated PWH, and to evaluate the impact of tenofovir. We conducted as a cross-sectional study between November 2020 and May 2021. Plasma samples from 4,400 of 5,476 PWH were tested for total antibodies, IgG, IgM, and IgA. Among the participants (median age 48 years, 84% male), 92% had undetectable HIV viral loads and 5% had syphilis. The prevalence of SARS-CoV-2 infection was 18% (95% CI 17-19), with 1,180 individuals showing antibodies (IgG 13%, IgA 10%, IgM 11%). Of those seropositive for SARS-CoV-2, 67.5% were asymptomatic, 29% had mild disease, and 3.5% had severe/critical conditions. Risk factors included younger age, being female, men who have sex with men (MSM) status, non-European origin, and a history of syphilis. Neither antiretrovirals nor tenofovir provided protection against SARS-CoV-2 infection or COVID-19 disease. Ongoing surveillance and tailored interventions are crucial for at-risk PWH amid evolving SARS-CoV-2 variants.</AbstractText><CopyrightInformation>Copyright © 2024. Published by Elsevier Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>de Lazzari</LastName><ForeName>Elisa</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>HIV Unit Infectious Diseases Service Hospital Clinic-IDIBAPS, University of Barcelona. Barcelona, Spain; CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nomah</LastName><ForeName>Daniel K</ForeName><Initials>DK</Initials><AffiliationInfo><Affiliation>Centre Estudis Epidemiològics sobre les Infeccions de Transmissió Sexual i Sida de Catalunya (CEEISCAT), Dept Salut, Generalitat de Catalunya, Badalona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blanco</LastName><ForeName>Jose L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>HIV Unit Infectious Diseases Service Hospital Clinic-IDIBAPS, University of Barcelona. Barcelona, Spain; CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rico</LastName><ForeName>Naira</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Core Laboratory. Biological Diagnostic Center. Hospital Clinic-IDIBAPS, University of Barcelona. Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Filella</LastName><ForeName>Xabier</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Core Laboratory. Biological Diagnostic Center. Hospital Clinic-IDIBAPS, University of Barcelona. Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Egri</LastName><ForeName>Natalia</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Immunology, Centre de Diagnòstic Biomèdic, Hospital Clínic of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruiz</LastName><ForeName>Raquel</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Core Laboratory. Biological Diagnostic Center. Hospital Clinic-IDIBAPS, University of Barcelona. Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marcos</LastName><ForeName>Maria Angeles</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain; Microbiology Department, Hospital Clinic of Barcelona, ISGlobal, University of Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mosquera</LastName><ForeName>Maria Del Mar</ForeName><Initials>MDM</Initials><AffiliationInfo><Affiliation>Microbiology Department, Hospital Clinic of Barcelona, ISGlobal, University of Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alcamí</LastName><ForeName>Jose</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>HIV Unit Infectious Diseases Service Hospital Clinic-IDIBAPS, University of Barcelona. Barcelona, Spain; CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sánchez-Palomino</LastName><ForeName>Sonsoles</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>HIV Unit Infectious Diseases Service Hospital Clinic-IDIBAPS, University of Barcelona. Barcelona, Spain; CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bruguera</LastName><ForeName>Andreu</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centre Estudis Epidemiològics sobre les Infeccions de Transmissió Sexual i Sida de Catalunya (CEEISCAT), Dept Salut, Generalitat de Catalunya, Badalona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hurtado</LastName><ForeName>Carmen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>HIV Unit Infectious Diseases Service Hospital Clinic-IDIBAPS, University of Barcelona. Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rovira</LastName><ForeName>Cristina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>HIV Unit Infectious Diseases Service Hospital Clinic-IDIBAPS, University of Barcelona. Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ambrosioni</LastName><ForeName>Juan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>HIV Unit Infectious Diseases Service Hospital Clinic-IDIBAPS, University of Barcelona. Barcelona, Spain; CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chivite</LastName><ForeName>Iván</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>HIV Unit Infectious Diseases Service Hospital Clinic-IDIBAPS, University of Barcelona. Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>González-Cordón</LastName><ForeName>Ana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>HIV Unit Infectious Diseases Service Hospital Clinic-IDIBAPS, University of Barcelona. Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Inciarte</LastName><ForeName>Alexy</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>HIV Unit Infectious Diseases Service Hospital Clinic-IDIBAPS, University of Barcelona. Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laguno</LastName><ForeName>Montserrat</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>HIV Unit Infectious Diseases Service Hospital Clinic-IDIBAPS, University of Barcelona. Barcelona, Spain; CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martínez-Rebollar</LastName><ForeName>María</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>HIV Unit Infectious Diseases Service Hospital Clinic-IDIBAPS, University of Barcelona. Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mora</LastName><ForeName>Lorena de la</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>HIV Unit Infectious Diseases Service Hospital Clinic-IDIBAPS, University of Barcelona. Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Torres</LastName><ForeName>Berta</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>HIV Unit Infectious Diseases Service Hospital Clinic-IDIBAPS, University of Barcelona. Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Díaz</LastName><ForeName>Yesika</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Centre Estudis Epidemiològics sobre les Infeccions de Transmissió Sexual i Sida de Catalunya (CEEISCAT), Dept Salut, Generalitat de Catalunya, Badalona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martínez</LastName><ForeName>Esteban</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>HIV Unit Infectious Diseases Service Hospital Clinic-IDIBAPS, University of Barcelona. Barcelona, Spain; CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mallolas</LastName><ForeName>Josep</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>HIV Unit Infectious Diseases Service Hospital Clinic-IDIBAPS, University of Barcelona. Barcelona, Spain; CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miro</LastName><ForeName>Jose M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>HIV Unit Infectious Diseases Service Hospital Clinic-IDIBAPS, University of Barcelona. Barcelona, Spain; CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain. Electronic address: jmmiro@ub.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Hospital Clinic HIV investigators</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>Int J Infect Dis</MedlineTA><NlmUniqueID>9610933</NlmUniqueID><ISSNLinking>1201-9712</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">HIV</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2, COVID-19, prevalence, risk factors, antiretroviral therapy, tenofovir, prognosis</Keyword></KeywordList><CoiStatement>Conflicts of interests JMM has received consulting honoraria and/or research grants from Angelini, Contrafect, Cubist, Genentech, Gilead Sciences, Jansen, Lysovant, Medtronic, MSD, Novartis, Pfizer, and ViiV Healthcare, all outside the current work. DKN received consultation fees from OPIS and is an employee of Aetion Iberia, both outside the current work. All other authors declared no conflicts.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>10</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>19</Day><Hour>16</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>19</Day><Hour>16</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>18</Day><Hour>19</Hour><Minute>18</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39423949</ArticleId><ArticleId IdType="doi">10.1016/j.ijid.2024.107266</ArticleId><ArticleId IdType="pii">S1201-9712(24)00337-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle>